|
Feb 14
|
Beyond the Balance Sheet: What SWOT Reveals About Bristol-Myers Squibb Co (BMY)
|
|
Feb 12
|
A Look at Pharma ETFs After Q4 Earnings
|
|
Feb 12
|
7 Dividend Stocks to Buy at a 52-Week Low
|
|
Feb 12
|
Bristol Myers Squibb and RayzeBio Announce Expiration of HSR Act Waiting Period
|
|
Feb 12
|
New Strong Sell Stocks for February 12th
|
|
Jan 16
|
Bristol Myers Squibb (BMY) Sees a More Significant Dip Than Broader Market: Some Facts to Know
|
|
Jan 10
|
Prothena's (PRTA) Update on Pipeline Progress Disappoints
|
|
Jan 10
|
5 questions facing pharma in 2024
|
|
Jan 9
|
Here's Why Bristol Myers Squibb (BMY) Fell More Than Broader Market
|
|
Jan 2
|
European Medicines Agency Validates Bristol Myers Squibb’s Application for Repotrectinib for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer and NTRK-Positive Solid Tumors
|
|
Dec 29
|
Stock Market Ending 2023 On High Note; Tesla, Drug M&A In Focus: Weekly Review
|
|
Dec 29
|
Is Bristol-Myers Squibb Company (NYSE:BMY) A High Quality Stock To Own?
|
|
Dec 28
|
Bristol Myers Squibb (BMY) Rises Yet Lags Behind Market: Some Facts Worth Knowing
|
|
Dec 28
|
Cytokinetics (CYTK) Up 83% as Cardiomyopathy Drug Meets Goals
|
|
Dec 28
|
Biotech Stock Roundup: BMY's KRTX and RYZB Acquisition, CYTK Surges on Study Data
|
|
Dec 28
|
Top 15 Value Stocks to Buy for 2024
|
|
Dec 28
|
11 Hot Healthcare Stocks To Buy Now
|
|
Dec 27
|
Cytokinetics Stock Skyrockets on Positive Results from Study of Its Heart Drug
|
|
Dec 27
|
FDA Rejects Amgen's (AMGN) NDA Seeking Full Nod for Lumakras
|
|
Dec 27
|
Bristol Myers (BMY) to Buy Cancer Drug-Maker RayzeBio for $4.1B
|